Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00512486 · ClinicalTrials.gov registry record · Phase 1

A Sequential Dose-Escalation Study in Subjects With Mild Asthma

A Phase 1 study, sponsored by MedImmune.

Completed
Registry status
Phase 1
Development phase
42
Enrollment target

NCT00512486 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 42 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00512486, a Phase 1 study, has completed, sponsored by MedImmune.

COMPLETED
Registry status
Phase 1
Development phase
42 participants
Enrollment target

Study Summary

The primary objective of this study is to investigate the safety of administration of this drug by increasing doses to male and female adult subjects with mild asthma.

Interventions

  • BIOLOGICAL MEDI-563

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2006-11
Est. Completion 2008-10
Phase Phase 1

Sponsor

MedImmune

210 total trials

What the Registry Record Tells You About NCT00512486

The ClinicalTrials.gov registry entry for NCT00512486 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which MEDI-563 is the first listed.

NCT00512486 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00512486 about?

NCT00512486 is a clinical study titled "A Sequential Dose-Escalation Study in Subjects With Mild Asthma". The primary objective of this study is to investigate the safety of administration of this drug by increasing doses to male and female adult subjects with mild asthma.

What is the current status of trial NCT00512486?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2006-11. Estimated completion is 2008-10.

What interventions are being tested in trial NCT00512486?

The interventions under investigation include: MEDI-563 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00512486?

This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.